These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21525888)

  • 1. A united front.
    Nature; 2011 Apr; 472(7344):389-90. PubMed ID: 21525888
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 3. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
    Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
    Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
    [No Abstract]   [Full Text] [Related]  

  • 4. In-process testing and limits.
    Sjöholm I
    Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685
    [No Abstract]   [Full Text] [Related]  

  • 5. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 6. March on, not in.
    Nat Med; 2011 May; 17(5):515. PubMed ID: 21546944
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality-by-design for biotechnology-related pharmaceuticals.
    Mandenius CF; Graumann K; Schultz TW; Premstaller A; Olsson IM; Petiot E; Clemens C; Welin M
    Biotechnol J; 2009 May; 4(5):600-9. PubMed ID: 19418475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial for Fabry disease faces continuing hurdles.
    Silversides A
    CMAJ; 2009 Nov; 181(11):E251-2. PubMed ID: 19825933
    [No Abstract]   [Full Text] [Related]  

  • 9. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality assurance and quality control for biopharmaceutical products.
    Geigert J
    Pharm Biotechnol; 2002; 14():361-404. PubMed ID: 12189728
    [No Abstract]   [Full Text] [Related]  

  • 11. Shire drops 'emergency' Fabry's disease drug.
    Fox JL
    Nat Biotechnol; 2012 Jun; 30(6):478. PubMed ID: 22678371
    [No Abstract]   [Full Text] [Related]  

  • 12. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
    Banikazemi M; Desnick RJ
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
    [No Abstract]   [Full Text] [Related]  

  • 13. NIH faces marching orders on orphan drug shortage.
    Dolgin E
    Nat Med; 2011 May; 17(5):522. PubMed ID: 21546953
    [No Abstract]   [Full Text] [Related]  

  • 14. Raw material considerations.
    Lubiniecki AS; Shadle PJ
    Dev Biol Stand; 1997; 91():65-72. PubMed ID: 9413684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry.
    von Stosch M; Davy S; Francois K; Galvanauskas V; Hamelink JM; Luebbert A; Mayer M; Oliveira R; O'Kennedy R; Rice P; Glassey J
    Biotechnol J; 2014 Jun; 9(6):719-26. PubMed ID: 24806479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturing of biopharmaceuticals and implications for biosimilars.
    Wurm FM
    Kidney Blood Press Res; 2007; 30 Suppl 1():6-8. PubMed ID: 17726336
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of benchmarking in the development of biopharmaceutical products.
    Giffin M; McLeish S
    Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 20. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
    Basic-Jukic N; Kes P; Mokos I; Coric M
    Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.